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Novel anticoagulants in the therapy of peripheral arterial and
coronary artery disease
Vincenzo Jacomella1, Natascia Corti2 and Marc Husmann1
Anticoagulant and antiplatelet drugs are used and studied in
numerous trials for primary and secondary prevention of
atherothrombosis since decades. The annual rate for
cardiovascular morbidity and mortality is high in patients
following an acute coronary syndrome and in patients with
peripheral arterial disease (PAD) due to concomitant cardiac
and cerebrovascular diseases. Plaque rupture and subsequent
thrombosis involves activation of both platelets and
coagulation factors. Therefore the combination of aspirin and
warfarin to improve prevention of atherothrombosis compared
to antiplatelet therapy alone was studied but could not be
established due to significantly increased risk of major bleeding
compared to a nonsignificant reduction in ischemic events.
During the past two decades, clinical trials focused on
combined antiplatelet therapies for the prevention of secondary
events following acute coronary syndromes and very recently
on the new oral anticoagulants in combination with antiplatelet
therapy. This review discusses the role of the new oral
anticoagulants such as Factor IIa (thrombin) and Factor Xa
inhibitors in atherothrombosis, their pharmacological
properties and recently published clinical data in secondary
prevention of atherothrombotic events and potential
implications for patients with PAD.
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Introduction
Atherothrombosis is defined as the occurrence of both
atherosclerosis and thrombosis in an artery and results in
myocardial, cerebral, limb, and reno-mesenteric ischemia
[1,2–4]. Among the atherosclerotic diseases, patients
with peripheral arterial disease (PAD) have an exten-
sively large atherosclerotic burden, often coexisting cor-
onary (CAD) and cerebrovascular disease, and have three
times increased risk for myocardial infarction or stroke as
patients without PAD [3,5]. Likewise, recurrent
ischemic events are as high as 10% per annum following
acute coronary syndrome [6,7]. Despite antiplatelet
therapy, up to 10–20% of these patients still have cardi-
ovascular events, indicating that the underlying athero-
thrombotic activity is not optimally controlled by
antiplatelet agents. Therefore, the combination of anti-
platelet therapy with oral anticoagulants to reduce ather-
othrombotic events has been studied in the Warfarin
Antiplatelet Vascular Evaluation trial (WAVE) for
patients with PAD [8,9]. This trial showed a nonsigni-
ficant reduction in ischemic events but a significant
increase in bleeding complications (RR 3.41; 95% CI,
1.84–6.35) during an observation period of 35 months.
The bleeding risk under combined antiplatelet and antic-
oagulant therapy is higher in PAD than in CAD without
PAD. This might be attributable to different factors such
as older age, vascular fragility, and higher morbidity
[10,11]. However, the combined antithrombotic therapy
is not recommended for atherothrombosis in general for
secondary prevention in PAD [12].
Currently in the dawn of a new anticoagulant era with
several new anticoagulants that have either specific antith-
rombin or anti-FXa activity — in contrast to Vitamin K
antagonists, that interfere in multiple ways in the coagu-
lation cascade — more numerous trials for prevention and
therapy of venous thromboembolism, prevention of
embolic complication due to atrial fibrillation and therapy
of atherothrombosis are reported and upcoming [13].
Besides the afore mentioned increased risk of bleeding
when combining antiplatelet drugs with Vitamin K
antagonists, their narrow therapeutic windows, need for
frequent laboratory monitoring, higher risk for food and
drug interactions pose several disadvantages. The de-
velopment of novel oral Factor Xa inhibitors and oral
direct thrombin inhibitors provide an alternative to Vita-
min K antagonists. In this paper, we discuss the new
agents, rivaroxaban, apixaban, and dabigatran, for second-
ary prevention of acute atherothrombosis and their thera-
peutic potential for patients with PAD and CAD.
Atherothrombosis and ischemia
Thrombosis plays a critical role in the pathomechanism of
ischemic syndromes, as disruption of an atherosclerotic
plaque exposes blood to subendothelial collagen, tissue
factor, and other procoagulant molecules such as throm-
bin that trigger activation of platelets and formation of
Available online at www.sciencedirect.com
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fibrin within the vessel lumen [14–16]. Not only endo-
thelial damage and dysfunction but also inflammation and
coagulation are closely related to the pathophysiology of
ischemic syndromes [17]. Platelets play key roles in both
the formation of the atheromatous plaque and clinical
presentation of acute atherothrombotic events following
plaque rupture. In the pathogenesis of atherothrombosis,
clotting activation has a crucial role and thrombin gener-
ation is involved in both platelet activation and fibrin
(Figure 1).
In animal models, hypercoagulability tends to increase
atherosclerosis, whereas hypocoagulability reduces the
atherosclerotic burden [18]. Whether this direct
relationship between coagulation and atherosclerosis
applies for humans is not clear. Almost all coagulation
proteins, including tissue factor, are found in athero-
sclerotic lesions in humans. In addition to generating
local fibrin, an environment for cell growth, serine pro-
teases such as thrombin are thought to be involved in cell
signaling processes, acting through the activation of pro-
tease-activated receptors [17]. Activation of such pro-
tease-activated receptors on vascular cells triggers other
complex processes promoting atherosclerosis, including
inflammation, angiogenesis, and cell proliferation.
Direct thrombin inhibitors and anti-FXa-inhibitors are
targeting at this crucial phase of thrombin generation with
the potential to prevent thrombosis and progression of
atherosclerosis alike. Therefore, the novel anticoagulants
may have synergistic antithrombotic and bleeding bal-
ance due to their pharmacodynamic and pharmacokinetic
properties which when combined with antiplatelet agents
may improve overall net effects. Furthermore, combined
therapy may be of benefit in aspirin resistance, which is
both a clinical and laboratory problem (Kasmeridis, Apos-
tollakis, Lip: aspirin and aspirin resistance in coronary
syndrome, in this issue of Current Opinion in Pharma-
cology).
Novel anticoagulants
In comparison to oral Vitamin K antagonist, either direct
inhibitors of thrombin or Factors Xa have overall favor-
able pharmacological effects. Examples of direct Factor
Xa inhibitors include apixaban, rivaroxaban, otamixaban,
betrixaban, and edoxaban. Direct thrombin inhibitors
(Factor IIa inhibitors) were developed with the limita-
tions of standard heparin and warfarin in mind. Examples
include ximelagatran, argatroban, and dabigatran etexi-
late. In common with these novel anticoagulants is the
convenience of use with no requirement for laboratory
monitoring and limited drug interactions, which may
provide multifaceted treatment options for atherosclero-
sis and anticoagulation in the future [13]. Because of
the data available, this review discusses the two anti-
Factor X inhibitors, rivaroxaban and apixaban, and the
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oral thrombin inhibitor dabigatran etexilate (Table 1)
[19,20–22]. There are differences between Factor Xa
and thrombin that may cause these clotting factors to be
affected differently by drugs that inhibit them. Currently,
the only known functions of Factor Xa are promotion of
coagulation and inflammation [23]. Thrombin has more
diverse actions in the body; in addition to its known
effects on coagulation and inflammation, thrombin also
activates protein C (which has anticoagulant properties)
and promotes cellular proliferation.
Rivaroxaban
Rivaroxaban is a direct Factor Xa inhibitor with high
plasma protein binding (92–95%). In a concentration-
dependent manner, rivaroxaban inhibits free Factor Xa
and prothrombinase-bound and clot-associated Factor Xa.
As a consequence, rivaroxaban prevents thrombin gener-
ation by inhibiting Factor Xa generated via both the
intrinsic and extrinsic coagulation pathways [4] but does
not exhibit direct effect on platelet aggregation induced
by collagen, adenosine diphosphate or thrombin [24].
The pharmacokinetic profile of rivaroxaban shows favor-
able safety and tolerability profile. The bioavailability of a
10 mg dose of rivaroxaban is high (80–100% when com-
bined with meal), and rivaroxaban is rapidly absorbed,
reaching a maximal plasma concentration (Cmax) within
two to four hours after oral administration (Table 1).
Rivaroxaban displays linear pharmacokinetics, with a
half-life of 7–11 hours in young subjects and 11–13 hours
in elderly subjects and no significant accumulation after
repeat dosing. Absorption is unaffected by food or anta-
cids. Furthermore, there is no inhibition or induction of
cytochrome-P-450 (CYPP450) isoforms. Although rivar-
oxaban is metabolized by CYP3A4, clinically significant
drug–drug interactions are only expected with strong
CYP3A4 inhibitors or inducers. Rivaroxaban is eliminated
in two-thirds through metabolic degradation in the liver,
half of which is excreted via the kidneys and half via the
hepatobiliary route. One-third of the dose is eliminated as
unchanged drug in the urine. There are no active circu-
lating metabolites of rivaroxaban.
Apixaban
Apixaban, like rivaroxaban, interrupts the coagulation
cascade by blocking the enzymatic activity of Factor
Xa [25,26]. Apixaban is a direct inhibitor of Factor Xa.
Orally administered apixaban reaches a bioavailability of
50% and Cmax is three to four hours (Table 1). The half-
life is 10–14 hours after repeated doses. Apixaban is
metabolized in part by CYP3A4; it is partly eliminated
by the kidneys (25%) and, to some extent, also processed
via CYP-independent mechanisms in the liver. Similarly
to rivaroxaban, apixaban does not induce or inhibit CYP
enzymes and has a low likelihood of clinically significant
drug–drug or food–drug interactions.
Dabigatran etexilate
Dabigatran directly inhibits both free and clot-bound
thrombin [13]. After oral administration the prodrug
dabigatran etexilate is rapidly converted to dabigatran
in the liver, with Cmax of 1.5 hours after oral ingestion
(Table 1). Dabigatran has a half-life of 14–17 hours at
steady state. In contrast to rivaroxaban, bioavailability is
low with only 7.2%, and therefore it is predominantly
excreted in the feces. Although part of the bioconversion
from prodrug to active metabolite occurs in the liver, the
CYPP450 system is not involved. As dabigatran is a
substrate of P-glycoprotein, potentially important drug
interactions with the P-glycoprotein inhibitors quinine/
quinidine and verapamil have been described. After
hepatic activation, 80% of dabigatran is eliminated in
the kidneys; thus, as for rivaroxaban and apixaban,
patients with severe renal impairment have been
excluded from most clinical trials.
Clinical data for the novel oral anticoagulants
in acute atherothrombosis
All three novel oral anticoagulants have been evaluated in
clinical trials for prevention of primary or secondary
venous thromboembolism, and nonvalvular atrial fibrilla-
tion. Rivaroxaban and arixaban have been investigated for
secondary prevention of atherothrombosis following
acute coronary syndromes in two phase III trials and
dabigatran in a phase II trial. Table 2 compares the results
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Table 1
Pharmacological properties of the new oral anticoagulants
Rivaroxaban Dabigatran Apixaban
Target molecule Factor Xa inhibitor Factor IIa inhibitor Factor Xa inhibitor
Prodrug No Yes No
Bioavailability (%) 80–100 3–8 52
Maximal plasma
concentration (Cmax) (hour)
2–4 0.5–2 1–3
Potential drug interactions Potent inhibitors of
CYP3A4 and P-gp
Quinidine, amiodarone,
potent P-gp inhibitors
Potent CYP3A4
inhibitors
Food interaction None None None
Half-life time (hour) 7–13 11–14 12
Renal elimination (%) 33 85 27
CYP3A4: cytochrome-P-450 3A4; P-gp: P-glycoprotein.
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of the two phase III trials with the novel anticoagulants in
acute coronary syndrome and of warfarin with aspirin in
patients with PAD.
Clinical data on rivaroxaban
Rivaroxaban has been approved not only for the preven-
tion of primary or recurrent venous thromboembolism but
also for prevention of systemic embolization in nonvalv-
ular atrial fibrillation [27–29]. However, the indication for
prevention of recurrence of atherothrombosis was
rejected in July 2012 by the Food and Drug Adminis-
tration due to increased bleeding risk in patients with a
recent acute coronary syndrome although rivaroxaban
reduced the risk of the composite end point of death
from cardiovascular causes, myocardial infarction, or
stroke [19]. Rivaroxaban increased the risk of major
bleeding and intracranial hemorrhage but not the risk of
fatal bleeding. In the ATLAS ACS 2-TIMI 51 trial, a
double-blind, placebo-controlled trial published early in
2012, approximately 15 000 patients with a recent acute
coronary syndrome received twice-daily doses of either
2.5 mg or 5 mg of rivaroxaban or placebo in addition to
aspirin which in 81% was combined with clopidogrel for a
mean of 13 months. The trials’ primary efficacy end point
was a composite of death from cardiovascular causes,
myocardial infarction, or stroke. An event rate of 8.9%
was observed for rivaroxaban and 10.7% for placebo
(hazard ratio 0.84; 95% confidence interval, 0.74–0.96;
P = 0.008), with significant event reduction for both the
twice-daily 2.5-mg dose (9.1% versus 10.7%, P = 0.02) and
the twice-daily 5-mg dose (8.8% versus 10.7%, P = 0.03).
Remarkably, the twice-daily 2.5-mg dose of rivaroxaban
reduced the rates of death from cardiovascular causes
(2.7% versus 4.1%, P = 0.002) and from any cause (2.9%
versus 4.5%, P = 0.002). In contrast, this survival benefit
that was not achieved with the twice-daily 5-mg dose. As
compared with placebo, rivaroxaban increased the rates of
major bleeding (2.1% versus 0.6%, P < 0.001) and intra-
cranial hemorrhage (0.6% versus 0.2%, P = 0.009), with-
out a significant increase in fatal bleeding (0.3% versus
0.2%, P = 0.66) or other adverse events. The twice-daily
2.5-mg dose resulted in fewer fatal bleeding events than
the twice-daily 5-mg dose (0.1% versus 0.4%, P = 0.04).
The striking finding of the ATLAS ACS 2-TIMI 51 trial
is that the survival benefit for rivaroxaban was only
observed with the 2.5-mg twice-daily dose, one quarter
of the dose studied in atrial fibrillation or venous throm-
boembolism, but again suggesting that higher doses may
offset the benefit with more bleeding events.
Clinical data on apixaban
The APPRAISE-2 trial (apixaban after acute coronary
syndromes) contrasts the ATLAS ACS 2-TIMI 51 trial
since it was stopped early due to a highly significant
increase in major bleeding without any relevant reduction
in ischemic events [30]. Only after a median follow-up
of 241 days, the primary outcome of cardiovascular death,
myocardial infarction, or ischemic stroke occurred in 7.5%
of the patients assigned to apixaban and in 7.9% assigned
to placebo (hazard ratio with apixaban, 0.95; 95% confi-
dence interval, 0.80–1.11; P = 0.51). The primary safety
outcome of major bleeding occurred in 1.3% of the
patients who received apixaban and in 0.5% with placebo
(hazard ratio with apixaban, 2.59; 95% confidence inter-
val, 1.50–4.46; P = 0.001). A greater number of intracranial
and fatal bleeding events occurred with apixaban than
with placebo (0.3/0.1% versus 0.1/0%).
Clinical data on dabigatran etexilate
There is only a dose findings study (phase II) for the
oral direct thrombin inhibitor dabigatran etexilate
(RE-DEEM) [31–33]. In the RE-DEEM trial, with
almost all patients receiving dual platelet inhibition, a
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Table 2
Ischemic and bleeding event rates in drug trials for peripheral arterial disease and acute coronary syndrome
Events (%) Peripheral arterial disease Coronary artery disease with acute coronary syndrome
WAVE APPRAISE-2 ATLAS ACS 2-TIMI 51
ASA ASA + warfarin Apixaban Placebo Rivaroxaban (2.5 mg) Placebo
Death, MI, stroke 13.3 12.2 8.8 8.9 9.1 10.7
Death MI, stroke, limb ischemia 17.4 15.9
Cardiovascular death 6 6.1 2.8 3.0 2.7 4.1
Major bleeding a2.2 a6.9 1.3 0.5 1.8 0.6
Fatal bleeding 0.3 0.9 0.1 0 0.1 0.2
Net events 19.6 22.8 10.1 9.4 10.9 11.3
Net deaths 6.3 7.0 2.9 3.0 2.8 4.3
WAVE denotes Warfarin Antiplatelet Vascular Evaluation (NCT00125671), mean follow-up 35 months (Ref. [8]).
APPRAISE-2 denotes Apixaban for Prevention of Acute Ischemic Events 2 (NCT00831441), mean follow-up 8 months (Ref. [31]).
ATLAS ACS2-TIMI 51 denotes Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary
Syndrome — Thrombolysis in Myocardial Infarction 51 (NCT00809965), mean follow-up 13 months (Ref. [9]).
In APPRAISE-2 and ATLAS ACS2-TIMI 51 standard therapy was aspirin with 81% and 93% that were on thienopyridine at time of randomization.
a Includes moderate bleedings. Life-threatening bleeding and fatal bleeding is 4.9% for combined therapy and 1.5% for antiplatelet therapy.
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dose-dependent increase in clinically relevant bleeding
events was observed, with highest rates with the dabiga-
tran etexilate 110 mg and 150 mg twice daily as currently
used in atrial fibrillation. The most frequently reported
bleeding events were gastrointestinal bleeding and
epistaxis. Although the study was not powered to demon-
strate efficacy in cardiovascular death, nonfatal myo-
cardial infarction or nonhemorrhagic stroke, lower
event rates was attained in the 2 higher dabigatran doses
(110 mg twice daily, 3.0%; 150 mg twice daily, 3.5%)
compared with the lower doses (50 mg twice daily,
4.6%; 75 mg twice daily, 4.9%) and the placebo group
(3.8%).
Clinical data on other emerging anticoagulants
Darexaban, another Factor IIa Inhibitor, was evaluated
for safety and tolerability for the prevention of ischemic
events in acute coronary syndromes [34]. Darexaban,
when added to dual antiplatelet therapy, produced a
dose-related twofold to fourfold increase in bleeding
versus placebo, with no other safety concerns, but also
with no efficacy.
Discussion
Two phase III studies were conducted for secondary
prevention of atherothrombotic events with rivaroxaban
and apixaban (the APPRAISE-2 trial and ATLAS ACS 2-
TIMI 51) — of which the APPRAISE was prematurely
terminated because of an excess of bleeding with apix-
aban and no evidence of benefit [19,30]. No phase III
trial was conducted with dabigatran because of similar
safety issues following the phase II study and because of
results suggesting an increased risk of myocardial ische-
mia [33]. Only the ATLAS ACS 2-TIMI 51 not only met
its primary objective but also a threefold to fourfold
increase in intracranial bleedings [31].
This differences in net event outcome between
APPRAISE-2 and ATLAS ACS 2-TIMI 51 are not well
explained by different bleeding rates, which were similar
in both trials. The APPRAISE-2 population was older and
more commonly, had diabetes, renal insufficiency, and
history of stroke, and more severe myocardial ischemia
[32]. There was no significant benefit in efficacy outcome
for death, myocardial infarction, or stroke in APPRAISE-2
(Table 2). Interestingly, FXa inhibition potency of the
studied doses was different: APPRAISE-2 used the same
5 mg twice daily apixaban dose tested in atrial fibrillation,
whereas ATLAS-2 used 2 doses (2.5 mg/5 mg twice
daily), that were one fourth to one half of the total daily
dose of rivaroxaban (20 mg once daily) tested in atrial
fibrillation. This might hypothetically suggest that a
lower, rather than a higher level of FXa inhibition per
se may have a better antithrombotic effect.
Taken together, the combination of a dual antiplatelets
therapy with a novel oral anticoagulant is associated with
dose-dependent increased risk for major and intracranial
bleeding risk and only with rivaroxaban with a signifi-
cantly lower rate of ischemic related deaths. Although the
American Food and Drug Administration did not approve
rivaroxaban for secondary prevention of acute coronary
syndrome, ATLAS ACS 2-TIMI 51 provides evidence
that reduction of the persistently high morbidity and
mortality after myocardial ischemia is possible
(Figure 2). Combination of antithrombotic therapy shifts
the ischemic-bleeding balance in a hyperbolic function
with slightly lower recurrent atherothrombosis but higher
risk for major bleeding, or vice versa if no anticoagulant is
added. Ideally, novel antithrombotic drug should
decrease recurrent atherothrombotic events without
increasing major bleedings. Nevertheless, the combi-
nation of only one antiplatelet agent (aspirin) with one
new oral anticoagulant — of which rivaroxaban at a
dosage of 2.5 mg twice daily seems to be the candi-
date — might be tempting for patient with PAD. In
contrast to patients with a recent acute coronary syn-
drome, patients with PAD at a chronic stage are not
treated by dual antiplatelets drugs irrespective of their
risk for atherothrombotic events. As mentioned above,
PAD patients are an atherosclerotic high risk group and
there are no trials for PAD patients evaluating the role of
combined anticoagulant therapy after acute events. How-
ever, due to the increased risk in PAD, a logic con-
sequence would be a trial — similar to the WAVE
study (warfarin and aspirin) — with aspirin and low dose
rivaroxaban [8]. With regard to the high incidence of
atherothrombotic events in this atherosclerotic subgroup,
an improved therapy for secondary prevention is still
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Schematic illustration of ischemia and bleeding risk in atherosclerosis in
dependence of antithrombotic regimen. The assumed hyperbolic
function indicates that in relation to antithrombotic regimen the risk shifts
either toward higher bleeding or higher ischemic risk. Ideally, the novel
antithrombotic drugs should shift the risk toward both lower ischemic
and bleeding rates (dotted line).
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needed for PAD. Themain safety issue with bleeding risk
will jeopardize the potential antithrombotic benefit, and
patients with PAD are usually older and more fragile.
Hence, PAD patients with previous history of cerebral
ischemia or major bleedings should be evaluated with
great caution. In contrast to WAVE trial with warfarin and
a target international normalized ratio of 2.0–3.0, a trial
with rivaroxaban 2.5 mg combined with aspirin represents
a lower bleeding risk, since 2.5 mg of rivaroxaban is a
quarter of the dosage that is used for atrial fibrillation.
In conclusion, atherothrombosis is often insufficiently
controlled by antiplatelet therapy alone. Combination
of antiplatelet agents with novel anticoagulants may
reduce ischemic events but is associated with an
increased risk for major bleedings. So far, no novel antic-
oagulant drug is approved for secondary prevention fol-
lowing acute coronary syndrome. PAD patients are a
fragile subgroup of atherosclerotic patients with substan-
tial risk for atherothrombotic events and need to be
carefully evaluated for combined antithrombotic therapy
with the novel anticoagulants.
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